Novel osteobiologics and biomaterials in the treatment of spinal disorders

Wellington K. Hsu; Christina L. Goldstein; Mohammed F. Shamji; Sam K. Cho; Paul M. Arnold; Michael G. Fehlings; Tom E. Mroz

doi:10.1093/neuros/nyw085

Novel osteobiologics and biomaterials in the treatment of spinal disorders

Wellington K. Hsu, Christina L. Goldstein, Mohammed F. Shamji, Sam K. Cho, Paul M. Arnold, Michael G. Fehlings, Tom E. Mroz

Research output: Contribution to journal › Article › peer-review

Abstract

Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.

Original language	English (US)
Pages (from-to)	S100-S107
Journal	Clinical Neurosurgery
Volume	80
Issue number	3
DOIs	https://doi.org/10.1093/neuros/nyw085
State	Published - Mar 1 2017
Externally published	Yes

Keywords

Bonemorphogenetic protein
Nanotechnololgy
Osteobiologics
Spinal biologics
Spinal fusion
TNF-α inhibitors

ASJC Scopus subject areas

Surgery
Clinical Neurology

Online availability

10.1093/neuros/nyw085

Library availability

Discover UIUC Full Text

Cite this

@article{52d856be2a4e4835afb9fbf626c3d85e,

title = "Novel osteobiologics and biomaterials in the treatment of spinal disorders",

abstract = "Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.",

keywords = "Bonemorphogenetic protein, Nanotechnololgy, Osteobiologics, Spinal biologics, Spinal fusion, TNF-α inhibitors",

author = "Hsu, {Wellington K.} and Goldstein, {Christina L.} and Shamji, {Mohammed F.} and Cho, {Sam K.} and Arnold, {Paul M.} and Fehlings, {Michael G.} and Mroz, {Tom E.}",

note = "Publisher Copyright: {\textcopyright} 2016 by the Congress of Neurological Surgeons.",

year = "2017",

month = mar,

day = "1",

doi = "10.1093/neuros/nyw085",

language = "English (US)",

volume = "80",

pages = "S100--S107",

journal = "Clinical Neurosurgery",

issn = "0148-396X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Novel osteobiologics and biomaterials in the treatment of spinal disorders

AU - Hsu, Wellington K.

AU - Goldstein, Christina L.

AU - Shamji, Mohammed F.

AU - Cho, Sam K.

AU - Arnold, Paul M.

AU - Fehlings, Michael G.

AU - Mroz, Tom E.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.

AB - Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.

KW - Bonemorphogenetic protein

KW - Nanotechnololgy

KW - Osteobiologics

KW - Spinal biologics

KW - Spinal fusion

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85031674956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031674956&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyw085

DO - 10.1093/neuros/nyw085

M3 - Article

C2 - 28350951

AN - SCOPUS:85031674956

SN - 0148-396X

VL - 80

SP - S100-S107

JO - Clinical Neurosurgery

JF - Clinical Neurosurgery

IS - 3

ER -

Novel osteobiologics and biomaterials in the treatment of spinal disorders

Abstract

Keywords

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this